41 participants with RA and T2D were randomised to recv anakinra or a TNFi; RA dz activity decreased in both groups over 6 mos. Anakinra significantly improved A1C at 3 and 6 mos, but TNFi did not. https://t.co/UIBsRjMbKR
Links:
Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 d…
https://buff.ly/2n3Mron
Sep-25-2019


